神经元特异性烯醇化酶对小细胞肺癌诊断的临床价值  

Clinical value of serum neuron specific enolase in small cell lung cancer

作　　者：任丽芬[1] 陈名声[1] 张志平[1] 刘田[1] 卢宝弼[1] 郝晓柯[1] 

机构地区：[1]第四军医大学西京医院检验科,陕西西安710032

出　　处：《现代肿瘤医学》2009年第12期2335-2337,共3页Journal of Modern Oncology

摘　　要：目的:探讨血清NSE对小细胞肺癌的诊断,分期及预后的临床价值,以及同时探讨标本溶血程度对NSE浓度的影响。方法:采用ELISA法,检测83例SCLC患者,63例肺良性疾病,62例正常对照及35例溶血标本的NSE水平。结果:SCLC组血清NSE水平(37.64±36.95)μg/L显著高于肺良性疾病组(11.94±4.19)μg/L和正常对照组(8.92±3.95)μg/L(P<0.01);SCLCⅢ,Ⅳ期患者血清NSE水平(53.58±40.87)明显高于Ⅰ,Ⅱ期(14.66±6.48)(P<0.01)。SCLC治疗前NSE水平显著高于治疗后(P<0.05)。以NSE水平为指标诊断SCLC的敏感性、特异性、准确性,分别为67.3%、83.1%和85.4%。标本溶血对NSE测定影响很大,并且随着溶血程度的增加NSE结果显著升高。结论:NSE可作为较好的小细胞肺癌肿瘤标志物,对SCLC诊断,尤其对临床分期及预后有重要参考价值。血清NSE值随溶血程度呈递增趋势,因此,应严格避免溶血,以减少假阳性的发生。Objective： To study the clinical value of serum neuro - specific enolase （NSE） in small cell lung cancer（SCLC） ,and the effects of hemolysis on serum neurospecific enolase（NSE） detection. Methods： To detect the level of NSE in the serum of 83 patients with small cell lung cancer（ SCLC ） ,63 patients with benign pulmonary dis- eases（BPD） ,62 patients in normal control group and 35 hematolytic samples,by ELISA. Results： The levels of NSE in the serum of SCLC group [ （37.64 ± 36.95 ） μg/L ] were significantly higher than those of the patients in BPD group [ （ 11.94 ± 4.19） μg/L ] and normal group [ （8.92 ± 3.95） μg/L ] （ P 〈 0.01 ） ; The levels of NSE in the stage Ⅲ,Ⅳ [ （53.58 ±40.87 ） μg/L ] were significantly higher than stage Ⅰ,Ⅱ （ 14.66 ± 6.48 ） （ P 〈 0.01 ）. After herapy, the levels of NSE were descanted obviously （P 〈 0.05 ）. The sensitivity, specificity and accuracy were 67.3% , 83.1% and 85.4% respectively. Hemolysis affected significantly the level of serum NSE,and increasing with the haemolytic degree. Conclusion： NSE can be used as a better - tumor marker in small cell lung cancer（SCLC） ,it may be useful for diagnosis, staging and prognosis in SCLC. The level of NSE in the serum increases with hemolysis.

关 键 词：神经元特异性烯醇化酶 小细胞肺癌 溶血 ELISA 

分 类 号：R734.2[医药卫生—肿瘤]